Predict your next investment

Asset/Investment Management
swz.com

See what CB Insights has to offer

Investments

3

Portfolio Exits

2

About Swiss Helvetia Fund

The Swiss Helvetia Fund is a non-diversified, closed-end investment company that invests in equity and equity-linked securities of Swiss companies. The Fund also may acquire and hold equity and equity-linked securities of non-Swiss companies in limited instances.

Swiss Helvetia Fund Headquarter Location

1270 Avenue of the Americas

New York, New York, 10020-1700,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Swiss Helvetia Fund

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Swiss Helvetia Fund in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Latest Swiss Helvetia Fund News

The Swiss Helvetia Fund, Inc. Announces Results Of The 2021 Annual Meeting Of Stockholders

Sep 14, 2021

Author: Sep 14, 2021 6:48 PM EDT NEW YORK, Sept. 14, 2021 /PRNewswire/ -- The Swiss Helvetia Fund, Inc. ( SWZ ) - Get Swiss Helvetia Fund Inc Report , a non-diversified registered closed-end investment company (the "Fund"), announced today that the 2021 Annual Meeting of Stockholders was held as scheduled and concluded. Based upon the voting results, 1) Andrew Dakos, Richard Dayan, Phillip F. Goldstein, Gerald Hellerman and Moritz A. Sell were elected as Directors to serve for a one-year term until the next annual meeting of stockholders and until his respective successor is duly elected and qualifies, 2) stockholders ratified the selection by the Fund's Board of Directors of Tait, Weller & Baker, LLP as the Fund's independent registered public accounting firm for the year ending December 31, 2021, and 3) a non-binding proposal by the Fund's Board of Directors to ratify approval by stockholders in 2006 to permit the Fund to leverage up to 10% of the Fund's total assets (including the amount borrowed) was approved. About The Swiss Helvetia Fund, Inc. The Fund ( www.swzfund.com ) is a non-diversified, closed-end investment company seeking long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. Its shares are listed on the NYSE under the symbol "SWZ." The Fund seeks to achieve its investment objective by investing generally in Swiss equity and equity-linked securities that are traded on a Swiss stock exchange, traded at the pre-bourse level of one or more Swiss stock exchanges, traded through a market maker or traded over the counter in Switzerland. The Fund also may invest in Swiss equity and equity-linked securities of Swiss companies that are traded on other major European stock exchanges. Closed-end funds, unlike open-end funds, are not continuously offered. Typically, shares of closed-end funds are sold in the open market through a stock exchange. Shares of closed-end funds frequently trade at a discount to net asset value. The price of the Fund's shares is determined by a number of factors, several of which are beyond the control of the Fund. Therefore, the Fund cannot predict whether its shares will trade at, below or above net asset value. The Fund is managed by Schroder Investment Management North America Inc. About Schroder Investment Management North America Inc. Schroder Investment Management North America Inc. and Schroder Investment Management North America Limited, investment advisors registered with the U.S. SEC, are units of Schroders plc (SDR.L), a global asset management company with approximately $832.2 billion in assets under management as of June 30, 2021. Schroder's clients include major financial institutions including banks and insurance companies, as well as local and public authorities, public and private pension funds, endowments and foundations, intermediaries and advisors, as well as high net worth individuals and retail investors. The firm has built one of the largest networks of offices of any dedicated asset management company with more than 500 portfolio managers and analysts covering the world's investment markets, offering a comprehensive range of products and services. Schroder Investment Management North America Inc. provides asset management products and services to clients in the U.S. and Canada. Schroder Investment Management North America Inc. is an indirect, wholly-owned subsidiary of Schroders plc, a U.K. public company with shares listed on the London Stock Exchange. This press release shall not constitute an offer to sell or a solicitation to buy, nor shall there be any sale of the Fund's shares in any state or jurisdiction in which such offer or solicitation or sale would be unlawful prior to registration or qualification under the laws of such state or jurisdiction. Contact:

Swiss Helvetia Fund Investments

3 Investments

Swiss Helvetia Fund has made 3 investments. Their latest investment was in Kuros Biosciences as part of their Series C on August 8, 2015.

CBI Logo

Swiss Helvetia Fund Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/18/2015

Series C

Kuros Biosciences

$15.3M

Yes

LifeCare Partners, LSP Life Sciences Partners, Omega Fund Management, and VI Partners

2

10/22/2010

Series C

Subscribe to see more

$99M

Subscribe to see more

10

1/19/2009

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/18/2015

10/22/2010

1/19/2009

Round

Series C

Series C

Series B

Company

Kuros Biosciences

Subscribe to see more

Subscribe to see more

Amount

$15.3M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

LifeCare Partners, LSP Life Sciences Partners, Omega Fund Management, and VI Partners

Sources

2

10

10

Swiss Helvetia Fund Portfolio Exits

2 Portfolio Exits

Swiss Helvetia Fund has 2 portfolio exits. Their latest portfolio exit was Kuros Biosciences on December 03, 2015.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/3/2015

Reverse Merger

4

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

12/3/2015

00/00/0000

Exit

Reverse Merger

Subscribe to see more

Companies

Subscribe to see more

Valuation

Acquirer

Subscribe to see more

Sources

4

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.